Recovery & Healing Preliminary Evidence
Thymosin Beta-4
Thymosin Beta-4
1 min read
Regulatory Status
🇺🇸 United States
Grey Area Part of the ongoing FDA review of compounded peptides.
FDA · Updated Apr 2026
🇬🇧 United Kingdom
Research Use Only Generally treated as research-only.
MHRA · Updated Apr 2026
🇦🇺 Australia
Restricted Restricted or prescription-only depending on channel.
TGA · Updated Apr 2026
🏅 WADA
Banned Restricted in sport due to performance and healing concerns.
WADA · Updated Apr 2026
Overview
Thymosin Beta-4 is the parent peptide associated with the shorter fragment often sold as TB-500. It is mostly discussed for wound-healing and tissue-repair applications, but it remains in the higher-risk bucket of the FDA conversation.
Research Snapshot
- Mechanistic interest centers on actin regulation and tissue repair
- Human evidence remains limited relative to the enthusiasm around the peptide
- Often confused with TB-500 in commercial marketing
Continue Reading